BioXcel Therapeutics, Inc.
BTAI
$4.98
-$0.25-4.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -89.13% | -71.13% | -2.66% | -37.24% | 141.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -89.13% | -71.13% | -2.66% | -37.24% | 141.58% |
| Cost of Revenue | 72.58% | -82.50% | 16.53% | 128.52% | 138.46% |
| Gross Profit | -98.75% | -69.32% | -37.87% | -459.06% | 141.76% |
| SG&A Expenses | -40.65% | -57.03% | -57.37% | -68.44% | -63.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.96% | -58.51% | -46.54% | -68.63% | -66.82% |
| Operating Income | 3.58% | 58.20% | 47.37% | 68.87% | 68.63% |
| Income Before Tax | -131.20% | 72.92% | 51.21% | 72.96% | 84.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -131.20% | 72.92% | 51.21% | 72.96% | 84.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.20% | 72.92% | 51.21% | 72.96% | 84.49% |
| EBIT | 3.58% | 58.20% | 47.37% | 68.87% | 68.63% |
| EBITDA | 3.58% | 58.38% | 47.55% | 68.99% | 68.73% |
| EPS Basic | 25.83% | 89.20% | 70.45% | 81.33% | 88.76% |
| Normalized Basic EPS | 17.30% | 89.20% | 70.54% | 81.97% | 89.92% |
| EPS Diluted | 25.83% | 89.20% | 70.45% | 81.33% | 88.76% |
| Normalized Diluted EPS | 17.30% | 89.20% | 70.54% | 81.97% | 89.92% |
| Average Basic Shares Outstanding | 211.72% | 150.60% | 65.11% | 44.83% | 37.92% |
| Average Diluted Shares Outstanding | 211.72% | 150.60% | 65.11% | 44.83% | 37.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |